This R21 proposal is a collaborative effort of Dr. Liu (University of North Carolina) and Dr. Park (Children's Hospital/Harvard Medical School) to investigate the role of heparan sulfate (HS) modifications in inhibiting Pseudomonas aeruginosa lung infection. HS is a highly sulfated polysaccharide present in large amounts on the cell surface and in the extracellular matrix. HS serves as an important regulatory factor in a wide range of biological processes, including cell adhesion, migration and proliferation, blood coagulation, and microbial infections. The overall hypothesis that will be tested in this proposal is that uniquely sulfated HSPG sequences differentially modulate bacterial pathogenesis and host defense mechanisms. Our preliminary studies demonstrated that a unique 3-O-sulfated HS, biosynthesized by the HS 3-O-sulfotransferase isoform 3 (3OST- 3), significantly inhibits P. aeruginosa lung infection in mice.
Specific Aim 1 will determine the biological basis of how 3-O-sulfated HS inhibits P. aeruginosa lung pathogenesis using a glycomics approach. We will determine the effects of 3-O-sulfation on the capacity of HS polysaccharides to regulate soluble antimicrobial factors, CXC chemokine-induced neutrophil recruitment, and anti-bacterial mechanisms of neutrophils. We will also determine if the expression of 3OST-3 is induced during P. aeruginosa infection as a host defense mechanism.
Specific Aim 2 will define the minimum structural features of HS oligosaccharides that inhibit P. aeruginosa lung infection, and determine if HS modification is a target for anti-P. aeruginosa pneumonia therapy. We will identify the 3-O-sulfated HS sequences that are most effective in inhibiting P. aeruginosa lung infection. Successful completion of these studies should provide a mechanistic foundation for the development of novel HS-based therapies against P. aeruginosa pneumonia.

Public Health Relevance

Pathogens establish the infection by exploiting heparan sulfate, a highly sulfated polysaccharide, present on the cell surface and extracellular matrix. This application will investigate the structural specificity of heparan sulfate for inhibiting infections caused by Pseudomonas aeruginosa. The results from study could lead to a better understanding on the bacterial infection mechanism and develop heparan-based antibacterial agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI074775-02
Application #
7898843
Study Section
Special Emphasis Panel (ZRG1-IDM-A (90))
Program Officer
Taylor, Christopher E,
Project Start
2009-08-01
Project End
2011-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
2
Fiscal Year
2010
Total Cost
$197,258
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Xu, Yongmei; Wang, Zhen; Liu, Renpeng et al. (2012) Directing the biological activities of heparan sulfate oligosaccharides using a chemoenzymatic approach. Glycobiology 22:96-106
Joglekar, M V; Quintana Diez, P M; Marcus, S et al. (2012) Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost 107:717-25
Sheng, Juzheng; Liu, Renpeng; Xu, Yongmei et al. (2011) The dominating role of N-deacetylase/N-sulfotransferase 1 in forming domain structures in heparan sulfate. J Biol Chem 286:19768-76
Liu, Renpeng; Liu, Jian (2011) Enzymatic placement of 6-O-sulfo groups in heparan sulfate. Biochemistry 50:4382-91
Xu, Yongmei; Masuko, Sayaka; Takieddin, Majde et al. (2011) Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science 334:498-501
Zhou, Xianxuan; Chandarajoti, Kasemsiri; Pham, Truong Quang et al. (2011) Expression of heparan sulfate sulfotransferases in Kluyveromyces lactis and preparation of 3'-phosphoadenosine-5'-phosphosulfate. Glycobiology 21:771-80
Peterson, Sherket B; Liu, Jian (2010) Unraveling the specificity of heparanase utilizing synthetic substrates. J Biol Chem 285:14504-13